Ignite Creation Date:
2025-12-24 @ 2:50 PM
Ignite Modification Date:
2026-06-27 @ 3:18 AM
Study NCT ID:
NCT06504459
Status:
RECRUITING
Last Update Posted:
2025-08-27
First Post:
2024-07-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Sponsor:
OHSU Knight Cancer Institute
Organization: